Bernstein analyst Lee Hambright lowered the firm’s price target on Johnson & Johnson to $158 from $160 and keeps a Market Perform rating on the shares following quarterly results. The firm acknowledges the solid Q4, but sees a tough setup for 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $152 from $166 at Wells Fargo
- Johnson & Johnson Reports Strong 2024 Financial Results
- Johnson & Johnson Earnings Report: Is it a Beat?
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Netflix, Seagate, J&J report quarterly beats: Morning Buzz